$LFST

DeLuca Teresa sold $250K of LFST

DeLuca Teresa sold 20,441 shares of LifeStance Health Group, Inc. (LFST) at $12.23 ($0.25M total) on 2026-08-13.

Original reporting
SEC EDGAR · DeLuca Teresa
Published Aug 14, 2026, 9:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LFST
Neutral
medium confidence
Mentioned
$LFST
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and resulting holdings; there is no linkage to earnings, guidance, litigation, or operational updates.

02

Market read

Traders may note the insider selling as a minor sentiment signal, but the filing alone is unlikely to drive repricing without other catalysts.

03

What to watch

The filing does not specify reasons for the sale, and the absence of a stated 10b5-1 plan does not, by itself, confirm intent or timing constraints.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-14, transaction dated 2026-08-13

Background

The article is a SEC Form 4 insider transaction disclosure for LifeStance Health Group, Inc.

Company-level read

Ticker impact

$LFSTNeutralMedium confidence
Context

LifeStance Health Group director DeLuca Teresa filed a Form 4 selling 20,441 shares at $12.23 on 2026-08-13.

Expected impact

Likely limited near-term impact; treat as a sentiment datapoint rather than a catalyst.

Evidence & confidence

The article contains only the transaction details (size, price, post-sale holdings) with no accompanying company news, and no 10b5-1 plan is indicated.

Market effects

No sector-level implications are provided beyond a single insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine liquidity events and may not reflect bearish views, especially without any accompanying negative company disclosure.

Key entities

  • LifeStance Health Group, Inc.

    Subject of the Form 4 insider sale disclosure.

  • DeLuca Teresa

    Director who sold 20,441 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LFSTMedAI 8/10

LifeStance Health Group, Inc. Q2 2026 Earnings Call Summary

LifeStance Health Group reported Q2 2026 revenue growth of 26%, driven by higher visit volumes and a 6% rise in revenue per visit, and said visits per clinician rose 7% YoY. The company raised full-year 2026 guidance to $1.685B-$1.725B revenue and 13.2% adjusted EBITDA margins, approved a new $100M buyback, and reported Q2 free cash flow of $88M.